Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Introduction: Convalescent plasma is a promising therapeutic option for corona virus disease 2019 (COVID-19). A recent study in 34 COVID-19 patients showed a reduction of recovered patients antibodies within 3 months of infection. The aim on this analysis was to evaluate the antibody titers and expl...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Politou, Marianna, Sergentanis, Theodoros N, Mentis, Andreas, Pappa, Vassiliki, Pagoni, Maria, Grouzi, Elisavet, Labropoulou, Stavroula, Charitaki, Ioanna, Moschandreou, Dimitra, Bouhla, Anthi, Saridakis, Stylianos, Korompoki, Eleni, Giatra, Chara, Bagratuni, Tina, Pefanis, Angelos, Papageorgiou, Sotirios, Spyridonidis, Alexandros, Antoniadou, Anastasia, Kotanidou, Anastasia, Syrigos, Konstantinos, Stamoulis, Konstantinos, Panayiotakopoulos, George, Tsiodras, Sotirios, Alexopoulos, Leonidas, Dimopoulos, Meletios A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
203.Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330323/
http://dx.doi.org/10.1182/blood-2020-136940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330323/
http://dx.doi.org/10.1182/blood-2020-136940

Ejemplares similares